Benefits of Breast Cancer Index

Susan K Boolbol, MD
Stephen C. Malamud, MD
Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer IndexSM (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.
Related Articles
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
2018 Third Annual Oncology Guide to New FDA Approvals
On March 13, 2017, the US Food and Drug Administration (FDA) approved ribociclib (Kisqali; Novartis), an oral CDK4/CDK6 inhibitor, in combination with letrozole for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala
|
2018 Third Annual Oncology Guide to New FDA Approvals
Efficacy of the Breast Cancer Navigator Role in Reducing Distress in Newly Diagnosed Breast Cancer Patients: A Pilot Study
Patricia Johnson, BS, RN, OCN, CBCN
|
May 2018 Vol 9, No 5
The authors present their findings from a study testing the effects of an early intervention by the Breast Cancer Navigator on distress.
Last modified: June 10, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code